|Prevent Diabetic Neuropathy Through Milgamma
|High blood pressure and sugar level can cause diabetic neuropathy
iabetic neuropathy is a severe complication that most diabetic patients suffer. Diabetic neuropathy patients suffer from both physical and psychological conditions due to nerve tissue damage caused by the decreased blood flow as well as high sugar level in the blood. Symptoms of diabetic neuropathy are often felt by patients after suffering 10 or 20 years of diabetes. In fact, almost 50% patients who suffer from diabetes develop this disease.
What is Diabetic Neuropathy?
Diabetic neuropathy has a lot of symptoms thus it is often difficult to diagnose this disorder at earlier stage. The symptoms of diabetic neuropathy often affect the digestive tract, extremities and general malaise. Often, patients report of experiencing problems with their bowel movement, muscle cramps and dizziness. It is important to take note that the symptoms of diabetic neuropathy vary depending on the type of nerves that are affected.
Diagnosis of diabetic neuropathy is through physical examination. Aside from looking into your blood sugar level, the doctor will also perform sensory tests and other tests to determine the health of your nerve endings. Such exams include the common ankle reflexes. Moreover, electrodiagnostic tests can also be done to determine whether the patient has diabetic neuropathy or not.
Due to the complication of this order, drugs are created in order to prevent the disease from getting worse. Aside from the administration of drugs, the blood sugar also needs to be controlled. There are a lot of drugs that can be used to treat the symptoms of diabetic neuropathy but one of the drugs that are very popular in treating this disorder is Milgamma. Milgamma is often administered to patients who are diagnosed earlier with diabetic neuropathy. It is a derivative from thiamine or Vitamin B1 (Jihong et al., 1999).
The Components Of Milgamma
Milgamma exist in three forms which are the dragees, injection and capsules. Milgamma contains the active ingredients which are the Benfotiamine, peroxidine and cyancobalaminum. The other components of Milgamma include silicone dioxide, cellulose, glycerides, maize starch and other sugar. The ratio of the active ingredients in Milgamma varies from one brand to the other. However, the usual dosage of Benfotiamine is 50 mg (Nash, 2009). Below is the dosage of active ingredients in Milgamma as indicated by Sadekov et al. (1998) and Simeonov et al. (1997)
It also resulted in significant improvement in indices of vibratory sensitivity along with data of cardiovascular tests characterizing parasympathetic control of heart rhythm. The sympathetic potentials on arms and legs having longer latent periods became very short. The overall study showed the improvement in 93% of the cases. Benfotiamine, a fat-soluble form of vitamin B1 (thiamine) better absorbed and stored in the tissues longer than the water-soluble tiaminhidroklorid.
Pyridoxine improves the loss of motor, sensory and vegetative nerve operation.
| ACTIVE SUBSTANCE
|Milgamma Neuro coated tablets
|Milgamma N capsules
|Milgamma coated tablets
Milgamma works by means of restricting the build up process of the blood sugar level in the different cells in the body. The cyanocobalamin is a Vitamin B12 while the pyroxidine is metabolized inside the body in order to split it to Vitamin B6. Vitamin B complex has a neurotropic and favorable effect on the nerves as well as the locomotor apparatus which makes Milgamma an effective drug that can improve the health of the nerves of the body. One of the known neurotropic effects of Vitamin B complex is the production of isonicotinic acid hydrazide which is effective in eliminating neuritides that can be damaging to the nerve endings of the body.
In the study conducted by Simeonov et al. (1997) tested 45 patients who suffered from peripheral polyneuropathy by administering Milgamma tablets for three months. The proponents of the study have noted that the efficacy of Milgamma is very high in patients who have been diagnosed early with diabetes compared to patients who were diagnosed of advanced neuropathy. Moreover, the study also indicated that there were no adverse effects following the administration of the drug.
Another study conducted that showed the efficacy of Milgamma was conducted by Jihong at al. (1999). Milgamma reduces the carboxymethyllysine (CML) which is responsible for the diabetic neuropathy. The study indicated that diabetic neuropathy is brought about by the increase of carboxymethyllysine (CML) and advanced glycation end product (AGE) which in turn cause damage to the different nerves of the body. The administration of Milgamma to patients with neuropathy resulted to the inhibition of the CML and AGE after the four weeks of administration of the drug. The proponents have indicated that Vitamin B6 is a known AGE inhibitor while the Benfotiamine was shown to lower down the CML and AGE in nerve tissues affected by diabetic neuropathy.
On the other hand, another related study conducted by Sadekov et al. (1998) showed that the efficacy of Milgamma in 14 patients who are suffering from diabetes mellitus Type II after six weeks. The intensity of the pain caused by neuropathy decreased after the six weeks of treatment. Moreover, the study also noted that there was an increasing conduction rate of excitation of the motor nerves thus resulted to the condition of the patients for up to 93%.
Side Effects Of Milgamma
Milgamma is yet to be approved by the FDA in the United States. However, other countries particularly the European nations have been using Milgamma as for treatment of diabetic patients. Although studies conducted regarding the efficacy of Milgamma did not reveal any side effects, it is important to take note that Milgamma can have possible adverse effects such as allergic reactions such as edema, rashes or hives can occur. Moreover, cardiovascular reactions such as palpitations, dizziness can also occur after taking this drug thus it is important to seek professional help prior to taking this drug. In fact, the different components found in Milgamma can have adverse effects to the health of an individual. It has been noted by Stratone et al. (2002) that Milgamma may interact with epinephrine, norepinephrine and cycloserine which can reduce the efficacy of Vitamin B6. On the other hand, the synthetic Benfotiamine is not compatible with iodide, iron, riboflavin and dextrose thus if you are taking other medications that contain these active ingredients, then Milgamma may render the other drug inefficient.
Caution When Taking Milgamma
Although pregnant and lactating women are advised to take in Vitamin B6 at 25 mg, they are not advised to take Milgamma the fact that it contains 100mg of Vitamin B6. Excessive amounts of Vitamin B6 can cause palpitations, insomnia and high blood pressure and these conditions are detrimental to pregnant women. In normal cases, the excess Vitamin B complex in humans is excreted through the urine thus reducing the risk of suffering from side effects. On the other hand, patients who are undergoing therapy for timorous forms of cancer are discouraged to take Milgamma. However, the reason as to why it is discouraged among cancer patients is yet to be known.
More about Milgamma
Drumeva, P., S. Pavlov and N. Deleval. 2002. Therapeutic Effect of Milgamma N in Symptomatic Neuralgia in the Course and After Herpes Zoster Ganglionitis. Scripta Scientifica Medica 34: 87-89.
Jihong, L., A. Alt, J. Liersch, R.G. Bretzel, M. Brownlee, H.P. 1999. Hammes. Benfotiamine Inhibits Intracellular Formation of Advanced Glycation End Products in vivo. Diabetologia 42: 603-607.
Nash, T. 2009. Treatment Options in Painful Diabetic Neuropathy. Acta Neurologica Scandinavica 100 (173): 36-42
Sadekov, R.A., A.B. Danilov and A.M. Vein. 1998. Diabetic Polyneuropathy Treatment By Milgamma-100 Preparation. Zh Nevrol Psikhiatr Im S S Korsakova 98(9):30-32.
Simeonov, S., M. Pavlova, M. Mitkov, L. Mincheva and D. Troey. 1997. Therapeutic Efficacy of "Milgamma" in Patients with Painful Diabetic Neuropathy. Folia Med (Plovdiv) 39(4):5-10.
Stratone, A., C. Stratone, R. Chiruta, F. Filip, O. Diaconu, O. Munteanu and F. Topoliceanu. 2002. The Effectiveness of Milgamma-N Therapy in Patients With Peripheral Diabetic Neuropathy. The Journal of Preventive Medicine 10 (4): 37-42.
MILGAMMA products Buy Here
Milgamma is a derivative from synthetic Vitamin B1.
This particular drug exists as an injectible, capsule or oral dragees.